Ethical aspects of clinical trials of blood clotting factors in children with hemophilia-Reference-Cited by-同舟云学术

Ethical aspects of clinical trials of blood clotting factors in children with hemophilia

Published:2022-04 Issue:2021(4) Volume: Page:
ISSN:
Container-title:Медицинская этика
language:en
Short-container-title:

Author:

Kudlay DA¹^ORCID,Vdovin VV²,Shiller EE³,Khokholov AL⁴,Davydkin IL⁵,Borozinets AYu⁶^ORCID

Affiliation:

1. I.M. Sechenov First Moscow State Medical University (Sechenov University), Russia, Moscow

2. Morozovskaya Children’s City Clinical Hospital, Russia, Moscow

3. Odintsovo Regional Hospital of the Moscow region, Russia, Odintsovo

4. Yaroslavl State Medical University, Yaroslavl, Russia

5. Samara State Medical University, Samara, Russia

6. AO “GENERIUM”, Russia, Vladimir region, Volginsky

Abstract

The proportion of drugs for use in juvenile patients is much less than for the adult population. This is due both to the lack of specific drugs for a number of childhood diseases, and the need to conduct special clinical studies in different age groups to assess safety and efficacy parameters. When developing a program for clinical trials of an orphan drug, ethical aspects of the participation of underage patients are considered, taking into account the current international and Russian legislation. Obtaining the informed consent of a minor patient from one of the parents requires detailed prior information and the establishment of a trusting relationship before the participation of a minor patient in a clinical trial. The results of clinical and observational studies of orphan drugs on the example of moroctocog alfa in previously treated pediatric patients with hemophilia A in different age groups contribute to an increase in the arsenal of drugs for the treatment of orphan diseases in the pediatric population and determine the optimal conditions for the use of moroctocog alfa in different age groups.

Publisher

Pirogov Russian National Research Medical University

Reference35 articles.

1. Vol’skaya E. Novye perspektivy dlya detskikh lekarstv. Remedium. 2007; 8: 6–11. Russian.

2. Zavidova SS, Namazova- Baranova LS, Topolyanskaya SV. Klinicheskie issledovaniya lekarstvennykh preparatov v pediatrii: problemy i dostizheniya. Pediatricheskaya farmakologiya. 2010; 7 (1): 6–14. Russian.

3. Mosikyan AA, Tomasheva AO, Galankin TL, Kolbin AS. Klinicheskie issledovaniya v pediatrii i neonatologii: uspekhi i prichiny neudach. Pediatricheskaya farmakologiya. 2016; 13 (3): 232–238. DOI: 10.15690/ pf.v13i3.1572. Russian.

4. Vdovin VV, Shiller EE, Svirin PV, Petrov VYu, Lavrent’eva IN, Perina FG, Kudlay DA, Shuster AM, Borozinets AYu. Osobennosti klinicheskikh issledovaniy rekombinantnykh faktorov svertyvaniya krovi IX u detey s gemofiliey B. Pediatriya im. GN Speranskogo. 2020; 99(3): 168–175. Russian.

5. Belousov YuB, Strachunskiy LS, Belousov DYu, Zubkov VV, Malaya IP, Gratsianskaya AN, Dorozhko OV, Popov AO. Voprosy etiki biomeditsinskikh issledovaniy v pediatrii. Farmateka. 2001; 5: 10–14. Russian.